Edition. Philadelphia. Lippincott Williams and Wilkins Publications; 2006.
p. 265.
2. Figgitt DP, Gillies PS, Goa KL. Levosimendan. Drugs
2001; 61: 613-627.
3. Remme WJ, Swedberg K and the Task Force for the
Diagnosis and Treatment of Chronic Heart failure, European Society of
Cardiology. Guidelines for the diagnosis and treatment of chronic heart
failure. Eur Heart J 2001; 22: 1527-1560.
4. Namachivayam P, Crossland DS, Butt WW, Shekerdemian
LS. Early experience with Levosimendan in children with ventricular
dysfunction. Pediatr Crit Care Med 2006; 7: 445-448.
5. Egan JR, Clarke AJ, Williams S, Cole AD, Ayer J,
Jacobe S, et al. Levosimendan for low cardiac output: A Pediatric
experience. J Intensive Care Med 2006; 21:.183-187.
6. Turanlahti M, Boldt T, Palkama T, Antila S, Lehtonen
L, Pesonen E. Pharmacokinetics of levosimendan in pediatric patients
evaluated for cardiac surgery. Pediatr Crit Care Med 2004; 5: 457-462.
7. Lechner E, Moosbauer W, Pinter M, Mair R, Tulzer G.
Use of levosimendan, a new inodilator, for postoperative myocardial
stunning in a premature neonate. Pediatr Crit Care Med. 2007; 8:
61-63.
8. Braun JP, Jasulaitis D, Moshirzadeh M, Doepfmer UR,
Kastrup M, von Heymann C, et al. Levosimendan may improve survival
in patients requiring mechanical assist devices for post-cardiotomy heart
failure. Crit Care 2006;10: R17.
9. Garratt C, Packer M, Colucci W, Fisher L, Massie B,
Teerlink J, et al. Development of a comprehensive new endpoint for
the evaluation of new treatments for acute decompensated heart failure:
results with levosimendan in the REVIVE I study. Crit Care 2004; 8: P89.
10. Mebazaa A, Nieminen M, Packer M, Cohen-Salal A,
Kleber F, Pocock S, et al. SURVIVE Investigators. Levosimendan vs
dobutamine for patients with acute decompensated heart failure: the
SURVIVE randomized trial. JAMA 2007; 297: 1883–1891.
11. Follath F, Cleland JG, Just H, Papp JG, Schoolz H,
Peuhkurinen K, et al.; Steering Committee and Investigators of the
Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety
of intravenous levosimendan compared with dobutamine in severe low-output
heart failure (the LIDO study): a randomised double-blind trial. Lancet
2002; 360: 196-202.
12. Moiseyev VS, Poder P, Andrejevs N, Ruda MY, Golikov
AP, Lazebriket LB, et al; RUSSLAN Study Investigators. Safety and
efficacy of a novel calcium sensitizer, levosimendan, in patients with
left ventricular failure due to an acute myocardial infarction. A
randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J
2002; 23: 1422- 1432.
13. Zairis MN, Apostolatos C, Anastasiadis P, Mytas D,
Katsaris C, Kouris N, et al. The effect of a calcium sensitizer or
an inotrope or none in chronic low output decompensated heart failure:
results drom the calcium sensitizer or inotrope or none in low output
heart failure study (CASINO). Program and abstracts from the American
College of Cardiology Annual Scientific Sessions 2004; March 7-10, 2004;
New Orleans, Louisiana. Abstract 835-6.
14. Andrea M, Jean-Louis T, Maurizio S, Baron VA, Rocco
H, Conti G, et al. Effects of Leosimendan on right ventricular
afterload in patients with acute respiratory distress syndrome: a pilot
study. Crit Care Med 2006; 34: 2287-2293.
15. Noto A, Giacomini M, Palandi A, Stabile L, Reali-Forster
C, Iapichano G, et al. Levosimendan in septic cardiac failure.
Intensive Care Med 2005; 31: 164-165.
16. Brierley J, Choong K, Cornell T, DeCaen A, Deymann
A, Doctor A, et al. 2007 American College of Critical Care Medicine
clinical practice parameters for hemodynamic support of pediatric and
neonatal septic shock. Crit Care Med 2009; 37: 1-23.
17. Harjola V-P, Peuhkurinen K, Nieminen MS, Niemala M,
Sunderberg G. Oral levosimendan improves cardiac function and
hemodynamicsin patients with severe congestive heart failure. Am J Cardiol
1999; 83: 4I–8I.
18. Poder P, Eha J, Sundberg S, Antila S, Heinpalu M,
Loogna I, et al. Pharmacodynamics and pharmacokinetics of oral
levosimendan and its metabolites in patients with severe congestive heart
failure: a dosing interval study. J Clin Pharmacol 2004; 44: 1143–1150.
19. Poder P, Eha J, Sundberg S, Antila S, Heinpalu M,
Loogna I, et al. Pharmacokinetic-pharmaco-dynamic
interrelationships of intravenous and oral levosimendan in patients with
severe congestive heart failure. Int J Clin Pharmacol Ther 2003; 41:
365-373.